SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, a foreign private issuer, reports a transaction in the company's own shares. The reporting period covers the month of April 2025, with the specific transaction date being April 29, 2025. The filing details a share repurchase executed through Citigroup Global Markets Limited on the London Stock Exchange.
Key Financial Metrics and Transaction Details
- Shares Purchased: 685,000 ordinary shares.
- Price Range: Lowest price paid was 1,404.50 GBp; highest price paid was 1,435.00 GBp.
- Average Price: Volume-weighted average price paid was 1,421.25 GBp.
- Treasury Shares: Following this purchase, GSK holds 204,104,458 ordinary shares in treasury.
- Shares Outstanding: 4,111,136,920 ordinary shares are in issue (excluding treasury shares).
- Voting Rights: Total voting rights remain at 4,111,136,920.
Note: This filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes and Program Status
The purchase was executed pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the company has purchased an aggregate of 35,034,155 ordinary shares. The shares acquired in this transaction are held as treasury shares.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described in the Risk Factors section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F. No specific new guidance or management commentary regarding operational outlook is provided in this document.
Key Facts for Investor Verification
- Verify the total remaining authorization under the share buyback program initiated on February 24, 2025.
- Confirm the impact of the increased treasury share count (204,104,458) on future Earnings Per Share (EPS) calculations.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for the specific risk factors referenced in the cautionary statement.
- Monitor subsequent filings to track the progress of the non-discretionary buyback agreement.